Preeclampsia

rosuvastatin

Effect of Rosuvastatin on the Clinical Features of Preeclampsia

Effect of Rosuvastatin on Sever Preeclampsia Induced Inflammatory Response

The primary outcome will be the effect of rosuvastatin on the resolution of biochemical features associated with severe PE (↑CRP and IL6).

Sara Mansour

assistant lecturer on anasthesia and icu department

Assiut University

. They will be randomly allocated into two equal groups of 40 parturient each: Group 1: 40 preeclamptic parturient receive 20 mg rosuvastatin orally once daily.
Group 2: 40 preeclamptic parturient receive 40 mg rosuvastatin orally once daily

computer generated randomization will be conducted in a Women's Health Hospital, Assuit University. Neither the doctor "investigator" nor the participant "parturient" will be aware of the group allocation or the drug used. The study drugs will be prepared by one of the supervisor anesthesia (not included in the procedure, observation or in data collection)

Ranibizumab patients will receive three monthly Ranibizumab 0.5 mg/0.05 mL injections, followed by PRN dosing, as treatment for acute pseudophakic cystoid macular edema.

Triamcinolone acetonide patients will receive PRN Triamcinolone acetonide 4 mg/0.1 mL injections, every 3 months, as treatment for acute pseudophakic cystoid macular edema.

CYSTOID MACULAR EDEMA

Intravitreal injection of Ranibizumab as treatment for acute pseudophakic cystoid macular edema. Ranibizumab patients will receive three monthly Ranibizumab 0.5 mg/0.05 mL injections, followed by PRN dosing, as treatment for acute pseudophakic cystoid macular edema.

Ranibizumab,

Intravitreal injection of Triamcinolone acetonide as treatment for acute pseudophakic cystoid macular edema. Triamcinolone acetonide patients will receive PRN Triamcinolone acetonide 4 mg/0.1 mL injections, every 3 months, as treatment for acute pseudophakic cystoid macular edema.

Triamcinolone acetonide

Soll Eye

Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide

To assess the safety of intravitreal R and T for the treatment of acute pseudophakic cystoid macular edema by evaluating:
Incidence and severity of ocular adverse events, as identified by eye examination
Incidence and severity of other adverse events, as identified by physical examination, subject reporting, and changes in vital signs

Mean change in spectral domain OCT CMT from baseline (microns)

Mean change in ETDRS letters from baseline (letters)

Proportion of patients with 3 line or better ETDRS letter improvement (%)

Time to 3 line ETDRS letter improvement (days)

Genentech, Inc.

Sprains and Strains

Contusions

each patient in this group will receive 90mg once daily, for the 14 days treatment.

etoricoxib 90mg 14 days

Patients in this group will receive 60mg of the drug, daily

etoricoxib 60mg daily for 14 days

Efficacy and Safety of Etoricoxib in Acute Ankle Sprain: A Double-Blind Comparative Study Among 2 Treatments Protocols

Efficacy and Safety of the Non-Steroidal Anti-Inflammatory Drug Etoricoxib in the Treatment of Acute Ankle Sprain in Sports: A Randomized Double-Blind Comparative Study Among 2 Treatments in the Acute Phase

oxygenase/edema

Effect of Rosuvastatin on the Clinical Features of Preeclampsia

Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide

Efficacy and Safety of Etoricoxib in Acute Ankle Sprain: A Double-Blind Comparative Study Among 2 Treatments Protocols

Baz done ki pi konplè remèd fèy medsin te apiye nan syans